Contents lists available at ScienceDirect

African Journal of Emergency Medicine

journal homepage: www.elsevier.com/locate/afjem



ORIGINAL ARTICLE

Factors associated with HIV testing among patients seeking emergent injury care in Kigali, Rwanda



Aly Beeman^{a,d}, Catalina Gonzalez Marques^b, Oliver Y. Tang^c, Chantal Uwamahoro^{d,*}, Spandana Jarmale^c, Zeta Mutabazi^d, Vincent Ndebwanimana^d, Doris Uwamahoro^d, Mediatrice Niyonsaba^{e,f}, Andrew Stephen^g, Adam R. Aluisio^{a,b}

^a Department of Emergency Medicine, Brown University Warren Alpert Medical School, Providence, RI, USA

^b Department of Emergency Medicine, Brigham & Women's Hospital, Boston, MA, USA

^c Brown University Warren Alpert Medical School, Providence, RI, USA

^d Department of Anaesthesia, Emergency Medicine and Critical Care, University of Rwanda, KN 4 Ave, Kigali, Rwanda

⁸ Department of Surgery, Brown University Warren Alpert Medical School, Providence, RI, USA

ARTICLE INFO

Keywords: Rwanda HIV Emergency care Global health Low- and middle-income countries

ABSTRACT

Introduction: Emergency centres (ECs) can be important access points for HIV testing. In Rwanda, one in eight people with HIV are unaware of their infection status, which impedes epidemic control. This could be addressed via increased testing. This cross-sectional study evaluated factors associated with EC-based HIV testing among injured patients at the Centre Hospitalier Universitaire de Kigali (CHUK), in Kigali, Rwanda.

Methods: Adult injury patients were prospectively enrolled between January-June 2020. Trained study personnel collected data on demographics, injury aspects, treatments, HIV testing, and disposition. The primary outcome was the completion of EC-based HIV testing. Differences between those receiving and those not receiving testing were assessed. Regression models yielding adjusted odds ratios with associated 95% confidence intervals (CI) were calculated to quantify magnitudes of effect.

Results: Among 579 patients, the majority were under 45 years of age (78.1%) and male (74.4%). The most common mechanism of injury was road traffic accidents (50.3%). EC discharge occurred in 54.4% of cases. HIV testing was performed in 221 (38.2%) cases, of which 5.9% had a positive result. HIV testing was more likely among males (aOR=1.69, 95% CI: 1.02-2.78; p=0.04), cases transported by prehospital services (aOR=2.07, 95% CI: 1.28-3.35; p=0.003) and those receiving surgical consultation (aOR=3.13, 95% CI: 1.99-4.94; p<0.001). Cases with lower acuity were less likely to be tested (OR=0.70, 95% CI: 0.55-0.90; p=0.004), as were those discharged (OR=0.28, 95% CI: 0.18-0.43; p<0.001).

Conclusion: In the population studied, most patients did not undergo HIV testing. EC-based physician directed testing was more likely among male patients and patients with greater care needs. These results may inform approaches to increase EC-based testing services in Rwanda and other similar settings with high HIV burdens.

Introduction

Substantial progress has been made in combatting HIV, yet HIV remains an ongoing global health challenge, disproportionally affecting those living in sub-Saharan Africa, where more than two-thirds of people living with HIV (PLHIV) reside [1,2]. Over the recent decade, strides have been made towards achieving the UNAIDS 90-90-90 targets, in which 90% of all people living with HIV will know their HIV status, 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy and 90% of all people receiving antiretroviral therapy will have viral suppression [3]. However, global data has shown that all 2020 targets have fallen short [3]. One of the potential drivers at play in not meeting these targets is that approximately one in eight people PLHIV in sub-Saharan Africa are unaware of their HIV status [4]. Early detection and treatment of HIV are linked to reductions in morbidity and mortality as well overall transmission. Testing is paramount in addressing the global epidemic [5].

HIV testing in sub-Saharan Africa has substantially expanded across multiple venues, however, gaps in testing access persist [4]. Emergency Centre (EC)-based HIV testing has the potential to help augment HIV

* Corresponding author.

https://doi.org/10.1016/j.afjem.2022.05.001

^e Rwanda Biomedical Center, Kigali, Rwanda

^f Service d'Aide Médicale Urgente (SAMU), Rwanda Ministry of Health, Kigali, Rwanda

E-mail address: uwmchantal@yahoo.fr (C. Uwamahoro).

Received 30 September 2021; Received in revised form 11 April 2022; Accepted 5 May 2022

²²¹¹⁻⁴¹⁹X/© 2022 The Authors. Published by Elsevier B.V. on behalf of African Federation for Emergency Medicine. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

test delivery [6]. ECs are unique contact points for HIV testing as they provide care to large numbers of patients that otherwise may not often interact within health systems. This is particularly true for injured patients which are predominantly men and younger individuals, key populations for HIV care engagement [7–10]. Furthermore, prior literature has reported high HIV prevalence among patients seeking general and injury-specific emergency care in low- middle- and high-income countries (LMIC), making the potential utility of EC-based testing provision even greater [6,11–13].

Within sub-Saharan Africa, Rwanda has been one of the leaders in addressing the HIV epidemic with its national response. The prevalence of HIV in Rwanda has been stable at 3% in the adult population, with approximately 220,000 PLHIV and with 90% of those treated attaining viral suppression [14–16]. Nevertheless, regional variations in the national program's success exist. In the capital of Kigali, HIV prevalence is at 7.3% [17]. Furthermore, up to one in eight PLHIV in Rwanda are not aware of their infection status, contributing to ongoing population transmission [18]. The identification of PLHIV in Rwanda, could be improve by further understanding the role of ECs in accessing at risk population and connecting them to HIV testing. This prospective cross-sectional study evaluated factors associated with EC-based physician directed HIV testing for injured patients at the Centre Hospitalier Universitaire de Kigali (CHUK), in Kigali, Rwanda.

Methods

Study design, setting & population

This prospective cross-sectional study was a pilot evaluation of ECbased HIV testing and was *a priori* nested within a prospective cohort study. The cohort study evaluated injury burdens and acute EC care at CHUK [19]. CHUK is the main public referral health facility and teaching hospital in the capital city of Kigali in Rwanda. CHUK has approximately 500 inpatient beds and an EC that provides continuous 24 h care and receives approximately 20,000 visits annually. Rwanda's only Emergency Medicine (EM) post-graduate training program is also housed within CHUK [20]. The research activities were approved by the CHUK ethics committee, the University of Rwanda College of Medicine and Health Sciences, and the institutional review board of Rhode Island Hospital.

All patients greater than or equal to 18 years of age presenting to the EC for injury care were eligible for inclusion. Pregnant patients, with concurrent medical needs unrelated to the index injury, legal prisoners of the state, and those unable or declining to provide informed consent were excluded.

The Rwandan Ministry of Health has set forth a comprehensive agenda to address the HIV epidemic which aims to achieve identification of PLHIV through testing as early as possible and linking these individuals to care in a timely manner [18]. In 2008, the Ministry of Health implemented provider-initiated testing and counselling as a national policy in order to increase the opportunity for HIV testing [32]. There are no national or hospital-based HIV testing guidelines specifically for the EC clinical setting at CHUK [28]. HIV testing processes in the EC entail patients to undergo a rapid HIV test; if the results are positive, a provider requests a blood sample for confirmation with an enzyme-linked immunosorbent assay (ELISA) laboratory test.

Data collection and management

All patients presenting to the CHUK EC were screened during the recruitment periods by protocol-trained research personnel who were present at the study site 24 h a day. Due to the COVID-19 pandemic, data collection was interrupted due to nationwide restrictions requiring a cessation of research activities. Data were thus acquired during two time periods: collection occurred from January 27th-March 21st, 2020 (pre-COVID19 study period) and from June 1st-June 28, 2020 (intra-COVID19 study period) [19].

Patients were screened after the clinical staff completed initial triage and stabilisation to not impede clinical care. Patients meeting study criteria were informed of the study and interested patients were enrolled after providing informed written consent in Kinyarwanda. A legally authorised patient representative provided informed consent if the patient was unable to due to illness or incapacity.

Research personnel collected data through the first six hours of EC clinical care using structured case reporting forms entered into a secure electronic database. Prospective data were collected on patient demographics and prior medical history, injury event characteristics, triage vital signs and mental status assessment (using the Glasgow Coma Score [GCS]), injury care, HIV testing, and EC disposition. Treatment interventions for injury care in the EC were coded as binary and aggregated with receipt of any single intervention resulting in an indication of treatment. Injury severity was characterised using the Kampala Trauma Score (KTS), a validated prognostic scale in LMIC settings [21,22]. A lower KTS (≤12) suggests a more severe injury state whereas a higher KTS (≥ 13) indicates a less severe injury condition [21]. Following earlier studies, serious injuries were defined as a traumatic pathology necessitating hospital admission. Number of serious injuries was based on each individual anatomical region as classified by the Abbreviated Injury Scale [23]. If data for HIV testing or disposition from the EC were not available within the first six hours of care, patient charts were reviewed retrospectively to extract this data. This was completed at the end of the enrolment phase using a validated patient linkage and data extraction approach as previously described [21].

Data analysis

Data were analysed using STATA version 15.0 (Stata Corp; College Station, USA). The primary outcome of interest was the completion of HIV testing in the EC. Variables of age, systolic blood pressure, and GCS were transformed into categorical data. The epidemiologic profile of the population was characterised using descriptive statistics. For summary statistics, continuous variables were described using median values with associated interquartile ranges (IQR) and categorical variables were described using frequencies and percentages. The prevalence of HIV testing and the proportion of patients with positive tests were calculated with associated 95% confidence intervals (CIS).

Significant differences between patients receiving and not receiving HIV testing were evaluated using χ^2 or Fisher's exact tests for categorical variables and Mann-Whitney tests for continuous variables. A multivariable stepwise backward logistic regression model was employed to identify factors associated with the provision of HIV testing. Variables that were statistically significantly different between HIV testing groups were included based on an *a priori* threshold of p<0.05. The backward stepwise regression was performed with model selection employing Akaike Information Criterion (AIC) for variable removal. To assess for potential collinearity among included variables, variance inflation factors (vif) were calculated, and no collinearity was observed (all vif < 10).

Due to the interruption in data collection stemming from the COVID-19 pandemic and its potential impacts on HIV testing, stratified analyses of the multivariable regression models were completed for the pre-COVID-19 and intra-COVID-19 periods. Additionally, average weekly case enrolments and HIV testing frequency were calculated and plotted (Python 3.6.8, Python Software Foundation) for the pre-COVID-19 and intra-COVID-19 periods.

Results

A total of 864 patients seeking care for injuries were screened for study inclusion. Of these, 579 patients consented, enrolled, and were included in the analysis. Of those enrolled, 221 received EC-HIV testing, and 358 did not (Fig. 1).




Fig. 1. Flow diagram for study population.

Patients were recruited from January 27th to March 21st and June 1st to June 28th, with a two-month period (March 22nd to May 31st 2020) of no study enrollment due to restrictions from the COVID-19 pandemic.

African Journal of Emergency Medicine 12 (2022) 281-286




Fig. 2. Average weekly cohort enrolment and HIV testing.

The median age of the study population was 33 years [IQR 26-43], and 74.4% were men. The primary mechanism of injury was road traffic accidents (50.3%). A total of 133 (23.0%) patients were transported by prehospital service, and the median hours between injury and presentation to the EC was four [IQR 1, 17]. The majority of patients (76.5%) required acute EC interventions, and 54.4% of patients had emergent surgical consultation. KTS scores ranged from 11 to 16, with 31 patients having a score scores < 12 indicating more severe injury states. For final EC disposition, 54.4% of patients were discharged, 40.6% were admitted to the hospital and 0.9% died (Table 1).

A prior diagnosis of HIV was reported by 2.3% of cases. HIV testing was performed for 38.2% of patients. Among those tested 13 (5.9%) had a positive test result. In bivariate analysis stratified by EC-HIV testing, men were more likely than women to be tested (p=0.001), as were those transferred from outside health facilities (p<0.001) or transported by prehospital services (p=0.009). Patients that were tested had a significantly longer time between injury and presentation (p<0.001), and lower KTS values (p<0.001). Patients receiving emergent EC interventions (p<0.001) or surgical consultation (p<0.001) during their first six hours of care were more likely to be tested. Patients were more likely to have received HIV testing if they were admitted to the hospital as compared to those not admitted (68.3% versus. 23.5%, p<0.001). In comparison of those who received HIV testing versus those who did not, there was no statistical difference in age (p=0.539), mechanism of injury (p=0.158) and any past medical history not due to injury (Table 1).

During the study period, average injury cases in the EC ranged from 33 to 66 patients per week, with HIV testing rates ranging from 9.1% to 31.5% per week. The mean number of patients enrolled per week was not significantly different in the pre-COVID-19 and intra-COVID-19 periods, at 50 versus 45 participants respectively (p=0.28) (Fig. 2). However, there was a significant difference in the proportion of patients who received HIV testing during the pre-COVID-19 period (74.3%) versus the intra-COVID-19 period (60.2%) (p<0.001) (Table 1).

In multivariable analysis EC-based HIV testing occurred with increased frequency among male patients (OR=1.69, 95% CI: 1.02–2.78; p=0.04), cases transported by prehospital services (OR=2.07, 95% CI: 1.28-3.35; p=0.003) and patients receiving surgical consultation (OR=3.13, 95% CI: 1.99-4.94; p<0.001). Cases with lower injury severity were less likely to undergo HIV testing (OR=0.70, 95% CI: 0.55-0.90; p=0.004), as were those discharged from the EC (OR=0.28, 95% CI: 0.18-0.43; p<0.001) (Table 2).

When limiting the analysis to patients enrolled during the pre-COVID 19 period, patients transported by prehospital services and receiving surgical consultation had a significantly greater likelihood of undergoing EC-based HIV testing, compared to those discharged from the EC (Supplemental Table 1). For cases captured during the intra-COVID-19 time period, those with increased time between injury and presentation had a greater odds of HIV testing, whereas those discharged from the EC had lower odds (Supplemental Table 2).

Discussion

This study evaluated factors associated with the provision providerdriven HIV testing among adult injured emergency centre patients at CHUK in Kigali, Rwanda. The results demonstrate that HIV testing occurred for a minority of injured patients in the emergency centre, and that those with more severe injuries and those admitted to the hospital had a higher likelihood of undergoing HIV testing. Conversely, those who were discharged and those with less severe injuries had a lower likelihood of completing EC-based HIV testing. These data may help inform approaches to HIV care engagement to increase EC-based testing services in Rwanda and other similar settings.

In the current study, one in five patients were less than 25 years of age. It is estimated that 10% of all new HIV infections will occur among young people aged 15-24 years. As the Republic of Rwanda has identified persons within this age group as a key population for testing due to the high risk of HIV infection, the EC care setting may represent an important venue to engage this demographic [17]. Studies have shown that the ECs can be highly effective settings for testing key populations who are more likely to present for injury care and do not often seek healthcare for non-emergent conditions [11,12,24,25]. In addition to young adults, EC-based HIV testing in Rwanda may also be an access point for other important populations such as men who have sex with men and intravenous drug users as seen in other settings [26,27]. As current Rwanda national HIV guideline do not address HIV testing in Emergency Care centres [28], there is a need for increased research from Rwanda on EC-based HIV care, in order to inform implementation approaches and guidelines that will maximise identification of PLHIV in the EC.

The current data found that HIV testing was more likely among those with more severe injuries, those requiring emergent EC interventions, and those admitted to the hospital. Although the cause of this is not certain it is possible that these severity factors influence clinical decisionmaking regarding HIV testing as these patients may require more invasive procedures such as surgery and may spend more direct time with physicians making them more likely to be tested by the provider-driven approach in the study setting. However, focusing testing efforts on these patients represents a missed opportunity to test patients discharged from the EC (the majority of patients presenting with injuries). While increasing delivery of EC-based HIV testing may have barriers due to competing priorities and complexities of implementation, other studies have found an increase in identifying PLHIV in need of treatment when HIV testing

Table 1

Population characteristics and characteristics by HIV test completion.

App:Use of the set	Variable	Number (%)(n=579)	Subjects Not Completing HIV Testing (n=358)	Subjects Completing HIV Testing (n=221)	P-Value
25-4437 (58,2%)21 (18,9%)16 (57,0%)37 (67,0%)35630 (0.0%)18 (3.0%)17 (7.%)0.00126631 (7.4,1%)10 (3.0%)27 (5.7%)1.0Fanair10 (2.5%)10 (3.0%)0.0.0%)2.0.0%)Fanair10 (2.5%)0.0.0%)0.0.0%)2.0.0%)Fanair10 (2.5%)0.0.0%)0.0.0%)2.0.0%)Signed Signed Signe	Age:				0.54
45-6492 (15.4%)15 (15.4%)71 (16.4%)71 (16.4%)SG16.0%)17 (15.4%)10.0Set17 (15.4%)10 (15.7%)10.0Maning19 (15.4%)10 (15.7%)10.0Maning Origonis lignica"0.00.0%)10.00.0010 (17.4%)40 (17.6%)10.00.0110 (17.4%)30 (0.0%)0.00.0240 (17.6%)10 (17.4%)10 (17.4%)0.0240 (17.6%)31 (17.4%)10 (17.4%)0.0230 (0.0%)10 (17.4%)10 (17.4%)0.0210 (17.4%)31 (17.4%)10 (17.4%)0.0210 (17.4%)31 (17.4%)10 (17.4%)0.0210 (17.4%)31 (17.4%)10 (17.4%)0.0210 (17.4%)31 (17.4%)10 (17.4%)0.0210 (16.4%)10 (17.4%)10 (17.4%)0.0210 (16.4%)10 (17.4%)10 (17.4%)10 (17.4%)210 (16.4%)11 (19.4%)11 (19.4%)10 (17.4%)210 (17.4%)10 (17.4%)10 (17.4%)10 (17.4%)311 (19.4%)10 (17.4%)10 (17.4%)10 (17.4%)311 (19.4%)10 (17.4%)10 (17.4%)10 (17.4%)311 (19.4%)10 (17.4%)10 (17.4%)10 (17.4%)311 (19.4%)10 (17.4%)11 (19.4%)10 (17.4%)311 (19.4%)11 (19.4%)11 (19.4%)10 (11.4%)3<	18-24	115 (19.9%)	74 (20.7%)	41 (18.9%)	
26536.0%)36.0%)70.7%)36.3%)Male47.0% A27.0% A37.0% AMale147.0% A27.0% A27.0% ASample147.0% A10.0% A27.0% ASample10.0% A27.0% A27.0% ASample10.17 A28.0% A27.0% ASample10.17 A28.0% A27.0% ASample10.17 A28.0% A27.0% ASample10.17 A28.0% A27.0% ASample11.1228.0% A27.0% ASample10.0% A27.0% A27.0% ASample24.40% A24.0% A20.0% ASample24.10% A24.0% A27.0% ASample24.0% A24.0% A20.0% ASample24.0% A24.0% A27.0% ASample24.0% A24.0% A20.0% ASample24.0% A24.0% A27.0% ASample24.0% A24.0% A20.0% ASample	25-44	337 (58.2%)	211 (58.9%)	126 (57.0%)	
Sec. 0.001 Mile 431 (74.4%) 277 (60%) 39 (16.7%)	45-64	92 (15.9%)	55 (15.4%)	37 (16.4%)	
Main Female147 (25,4%)147 (25,4%)147 (25,4%)147 (25,4%)Bissing107 (25,4%)10,0%)00,0%)70,0%)Minser of scions hjurics'101 (17,4%)260 (78,2%)66 (72,4%)1107 (76,0%)260 (78,2%)66 (72,4%)100,0%)1281 (26,0%)62 (27,4%)100,0%)2281 (26,0%)62 (27,4%)100,0%)2201 (26,0%)62 (27,4%)100,0%)2201 (26,0%)201 (26,0%)201 (26,0%)2201 (26,0%)201 (26,0%)201 (26,0%)-000201 (26,0%)201 (26,0%)201 (26,0%)-000201 (26,0%)201 (26,0%)201 (26,0%)-00110,0%)10 (26,0%)201 (26,0%)-00220 (26,0%)10 (26,0%)201 (26,0%)-01310 (27,0%)10 (26,0%)10 (26,0%)-01410 (27,0%)10 (26,0%)10 (26,0%)-01526 (26,0%)10 (26,0%)10 (26,0%)-01626 (26,0%)12 (26,0%)12 (26,0%)-01626 (26,0%)12 (26,0%)12 (26,0%)-01626 (26,0%)12 (26,0%)12 (26,0%)-01626 (26,0%)12 (26,0%)12 (26,0%)-01626 (26,0%)12 (26,0%)12 (26,0%)-01626 (26,0%)12 (26,0%)12 (26,0%)-01626 (26,0%)12 (26,0%)12 (26,0%)-01626 (26,0%)12 (26,0%)12 (26,0%)-01626 (26,0%)12 (26,0%)12 (26,0%)	≥65	35 (6.0%)	18 (5.0%)	17 (7.7%)	
<table-container>Famile10 (0.3%)0.7(1.5%)0.7(1.5%)Number10.2%)62.0%)62.0%)Number Of Seriou Liptical11.7.4%)46.1.2%)81.6.2%)7.2.4%)2110.1.7.4%)20.0%)10.2%)7.2.4%)7.2.4%)2110.1.7%21.0%)10.2%%)7.2.4%)7.2.4%)2110.1.7%21.0%)10.2%%)7.2.4%)7.2.4%)22.5%101 Mod Present (Imm Mark 2000)21.0%)10.2%%)7.2.4%)7.2.4%)23.6%101 Mod Present (Imm Mark 2000)21.0%%)10.1%%)7.2.4%)7.2.4%)23.6%101 Mod Present (Imm Mark 2000)21.0%%)10.1%%)7.2.4%%)7.2.4%%)23.7%102 Mod Present (Imm Mark 2000)21.0%%)10.1%%)7.2.4%%)7.2.4%%)23.8%102 Mod Present (Imm Mark 2000)11.2 (1.5.4%)11.2 (1.5.4%)7.2.4%%)7.2.4%%)23.8%102 Mod Present (Imm Mark 2000)11.2 (1.5.4%)11.2 (1.5.4%)7.2.4%%)7.2.4%%)24.12%103 Mod Present (Imm Mark 2000)11.2 (1.5.4%)11.2 (1.5.4%)7.2.4%%)7.2.4%%)24.12%104 Mod Present (Imm Mark 2000)11.2 (1.5.4%)11.2 (1.5.4%)7.2.4%%)7.2.4%%)24.12%104 Mod Present (Imm Mark 2000)11.2 (1.5.4%)11.2 (1.5.4%)7.2.4%%)7.2.4%%)24.12%104 Mod Present (Imm Mark 2000)11.2 (1.5.4%)11.2 (1.5.4%)7.2.4%%)7.2.4%%)7.2.4%%)24.12%104 Mod Present (Imm Mark 2000)11.2 (1.5.4%)11.2 (1.5.4%)7.2.4%%)7.2.4%%7.2.4%%)24.12%104 Mod Present (Imm Mark 2000</table-container>	Sex				0.001
Famile10 (33.%)70 (10.%)70 (10.%)70 (10.%)Number10.03%)50 (2.9%)50 (2.9%)50 (2.9%)Value40 (2.9%)20 (9%)60 (2.7%)50 (2.9%)2130 (0.9%)20 (9%)60 (2.7%)50 (2.9%)50 (2.9%)Parsentation40 (1.9%)20 (9%)60 (2.7%)50 (2.9%)50 (2.9%)Parsentation50 (0.9%)20 (9.9%)20 (9.9%)50 (2.9%)50 (2.9%)Parsentation50 (0.9%)20 (9.9%)20 (9.9%)50 (9.9%)50 (9.9%)Parsentation50 (0.9%)20 (9.9%)50 (9.9%)50 (9.9%)50 (9.9%)50 (1.9%)51 (1.9%)20 (9.9%)50 (9.9%)50 (9.9%)50 (9.9%)51 (1.9%)52 (0.9%)51 (1.9%)50 (9.9%)50 (9.9%)50 (9.9%)52 (2.9%)51 (1.9%)51 (1.9%)50 (9.9%)50 (9.9%)50 (9.9%)53 (2.9%)52 (2.9%)52 (9.9%)50 (9.9%)50 (9.9%)50 (9.9%)54 (2.9%)52 (2.9%)52 (9.9%)50 (9.9%)50 (9.9%)50 (9.9%)54 (2.9%)52 (2.9%)52 (9.9%)50 (9.9%)50 (9.9%)50 (9.9%)55 (2.9%)52 (2.9%)52 (9.9%)50 (9.9%)50 (9.9%)50 (9.9%)56 (2.9%)52 (2.9%)52 (9.9%)50 (9.9%)50 (9.9%)50 (9.9%)56 (2.9%)52 (2.9%)52 (9.9%)50 (9.9%)50 (9.9%)50 (9.9%)56 (2.9%)52 (2.9%)52 (9.9%)50 (9.9%)50 (9.9%)50 (9.9%) <td>Male</td> <td>431 (74.4%)</td> <td>247 (69.0%)</td> <td>184 (83.3%)</td> <td></td>	Male	431 (74.4%)	247 (69.0%)	184 (83.3%)	
<table-container>Minking10.2%)10.2%)10.2%)00010.17.4%)40.12.4%)50.42.4%)10.12.4%)140.076.0%)20.072.3%)61.27.4%)51.27.4%)140.076.0%)20.072.4%)61.27.4%)51.27.4%)110.12.1%10.12.4%)51.27.4%)51.07.4%)210.12.1%10.12.4%)51.07.4%)50.07.4%210.12.1%10.12.1%)10.07.4%)10.07.4%)210.12.1%10.12.1%10.07.4%)10.07.4%)2.0010.12.1%10.12.1%10.07.4%)10.07.4%)3.0010.12.1%10.12.1%10.12.1%10.12.1%3.1010.14.1%10.14.1%10.14.1%10.14.1%3.1110.14.1%10.14.1%10.14.1%10.14.1%3.1220.14.1%10.14.1%10.14.1%10.14.1%3.1310.14.1%10.14.1%10.14.1%10.14.1%3.1410.14.1%10.14.1%10.14.1%10.14.1%3.1520.14.1%11.15.0%10.14.1%10.14.1%3.1520.14.1%11.15.0%11.15.0%10.14.1%3.1610.14.1%10.14.1%10.14.1%10.14.1%3.1610.14.1%10.14.1%10.14.1%10.14.1%3.1610.14.1%10.14.1%10.14.1%10.14.1%3.1610.14.1%10.14.1%10.14.1%10.14.1%3.1610.14.1%10.14.1%10.14.1%10.14.1%3.1610.14.1%10.14.1%<td>Female</td><td></td><td></td><td></td><td></td></table-container>	Female				
NumberUnit of serious problemUnit of the series of	Missing				
010 17.4%)40 (12.4%)55 (24.9%)21440 (26.6%)26.7%)62.7%)2446.0%)20.6%2%)62.7%)1500 Retween highny and4.1.1221.8.9%62.7%)1500 Retween highny and4.1.1235.7%2%)61.2%21500 Retween team high and57.7%7%)87.9%%7.0%1%1500 Retwee team high and91.6%1%21.3.9%10.3%92500 Retwee team high and54.2.9%2%21.9.9%3%21.9.9%3%260 Retwee team high and54.2.9.3%2%21.9.9%3%21.9.9%3%251 Set	0				< 0.001
1400 (75,0%)280 (75,2%)160 (72-%)Hour Between Injury and41-1731 (5-%)81-5-%)<0.001		101 (17.4%)	46 (12.9%)	55 (24.9%)	
2+38 (6.6%)32 (8.9%)6 (2.7%)					
Hour Reven Injury and Presentation: Median (QR)3 [1-2]8 [2-26]collSystoit Road Pressure (mr 1g):					
<table-container>0.02Stotick is 00 resource many Stotick is 00 resourc</table-container>					<0.001
İndemin (1000)'070 (08,4%)'077 (08,4%)'07.0%20(1.6%)10.3%)23 (06.4%)-30(1.6%)'1.0.3%)210 (6.4%)-3124 (03,6%)35 (08,0%)101 (6.4%)34(1.1.0%)10.3%)10 (4.5%)-38(11.0%)10.3%)10 (4.5%)-39.1224 (4.3%)10.3%)10 (4.5%)-38.11(1.4.15)10.3%)10 (4.5%)-39.1150.0%112 (50.7%)0.001(10.11-1.2.0%)112 (50.7%)	Presentation: Median (IQR)			0 [1 10]	
29091,290,10,230,21,236,4%)-50Glagor Cona Scale		570 (98.4%)	357 (99.7%)	8 (3.6%)	
-00-00-00-0013-15542 (93.6%)31 (98.0%)191 (86.4%)-0113-1514 (15%)61.7%)20 (9.1%)-013-811 (1.9%)10.0%)10 (4.5%)-013-811 (1.9%)15 [14-15]14 (14-15)-0.001(00)-00.0%12 (50.7%)-00.0%-00.0%(10)254 (43.9%)14 (20.97%)12 (50.7%)-00.0%No-00.0%12 (50.7%)-00.0%-00.0%No-00.0%216 (60.3%)77 (34.8%)-00.0%No-00.0%20.0%77 (34.8%)-00.0%No-00.0%20.0%77 (34.8%)-00.0%No-00.0%20.0%77 (34.8%)-00.0%No-00.0%20.0%77 (34.8%)-00.0%No-00.0%20.0%10.0%-00.0%No-00.0%20.0%10.0%-00.0%No-00.0%20.0%10.0%-00.0%No-00.0%10.0%10.0%-00.0%No-00.0%10.0%10.0%-00.0%No-00.0%10.0%10.0%-00.0%No-00.0%10.0%10.0%-00.0%No-00.0%10.0%10.0%-00.0%No-00.0%10.0%10.0%-00.0%No-00.0%10.0%10.0%-00.0%No-00.0%10.0%10.0%-00.0%No-00.0%20.0%10.0%-00.0% <t< td=""><td></td><td></td><td></td><td></td><td></td></t<>					
Glagowan Scale		2 (21070)	1 (0.070)	210 (3011)0)	
13-15542 (93.6%)31 (98.0%)19 (184.%)19 (184.%)3-811 (1.9%)(0.3%)10 (3.1%)3-811 (1.9%)15 [14-15)10 (1.4%)(DR)15 [14-15)14 (14-15)(DR)254 (43.9%)12 (39.7%)12 (50.7%)Patient Transfored from Another25 (43.9%)12 (10.7%)No254 (43.9%)12 (10.5%)Patient Transfored by Perkopital26 (10.9%)77 (34.9%)No6 (10.9%)208 (63.2%)77 (34.9%)Services410 (9.6%)208 (63.2%)12 (10.6%)No6 (10.9%)208 (63.2%)12 (10.6%)No6 (10.9%)90 (84.9%)10 (10.9%)No10 (29.6%)10 (29.6%)10 (29.6%)No10 (29.6%)10 (29.6%)10 (29.6%)Palmonery Condition10 (29.7%)10 (29.6%)10 (29.6%)Nordificion10 (29.7%)20 (80.9%)10 (69.6%)Diabers50 (9.6%)20 (9.6%)10 (9.6%)Diabers50 (9.6%)20 (9.6%)10 (9.6%)Diabers50 (9.6%)20 (9.6%)10 (9.6%)Diabers50 (9.6%)20 (9.6%)10 (9.6%)Diabers50 (9.6%)20 (9.6%)10 (9.6%)					<0.001
9-1226 (4.5%) 1 (0.9%)10.03%) 10 (4.5%)10 (4.5%)3-815 (1-15)15 (1-15)14 [1-15]<0.001		542 (93.6%)	351 (98.0%)	191 (86 4%)	10.001
3-811 (1.9%)10 (19%)14 (14-15)14 (14-15)0.00 (10%)(DOR)15 (14-15)15 (14-15)14 (14-15)0.00 (14-15)(DOR)254 (43.9%)14 (2.97.7%)109 (49.3%)0.00 (14-15)No255 (56.1%)16 (3.9%)109 (49.3%)0.00 (14-15)No253 (56.1%)256 (15.0%)77 (3.48.%)0.00 (14-15)Services133 (3.0%)298 (32.9%)142 (64.3%)0.00 (14-15)Services133 (23.0%)298 (32.9%)142 (64.3%)0.99No6 (1.0%)298 (32.9%)142 (64.3%)0.99No6 (1.0%)298 (32.9%)16 (2.6%)0.99No6 (1.0%)203 (34.6%)187 (34.6%)0.99No6 (1.0%)203 (34.6%)187 (34.6%)0.99HW30 (2.9%)10 (2.9%)0.830.99HW13 (2.9%)12 (2.9%)14 (3.9%)0.32Palmonary Condition6 (1.0%)2 (2.9%)14 (3.9%)0.32Palmonary Condition1 (0.2%)1 (0.9%)0.320.98Neurologic Condition1 (0.9%)0 (0.0%)0.420.00Neurologic Condition1 (0.9%)2 (0.9%)0.160.02Diabetes0 (0.0%)2 (0.9%)10 (0.9%)0.16Neurologic Condition1 (0.9%)2 (0.9%)0.160.01Neurologic Condition1 (0.9%)2 (0.9%)0.160.01Neurologic Condition1 (0.9%)2 (0.9%)0.160.01 <td< td=""><td></td><td></td><td></td><td></td><td></td></td<>					
Kampla Trauna Score: Median15 (14-15)14 (14-15)<0.001Patient Transferred from Another0009Patient Transferred from Another122 (39.7%)112 (50.7%)Na325 (56.1%)216 (60.3%)109 (49.3%)No333 (23.0%)56 (15.6%)77 (34.8%)Services440 (76.0%)29 (83.2%)142 (64.3%)Services400 (76.0%)29 (83.2%)142 (64.3%)No401 (23.5%)8 (22.9%)15 (24.6%)0.99Past Medical History*12 (2.3%)8 (2.2%)0.99Roma (20.0%)142 (3.4%)0.9931 (2.3%)0.99Cardiac Condition13 (2.3%)8 (2.2%)15 (2.4%)0.99Roma (20.0%)10 (2.3%)12 (3.4%)0.3531 (3.6%)0.99Cardiac Condition13 (2.3%)12 (3.4%)0.16 (3.4%)0.35Roma (20.0%)10 (2.3%)10 (2.5%)0.00%)0.43Pathomary Condition10 (2.5%)10 (2.5%)0.27Roma (20.0%)10 (0.0%)0.16 (3.4%)0.27Roma (20.0%)10 (0.0%)10 (2.5%)0.27Roma (20.0%)28 (0.7%)19 (6.0%)0.16Namely (20.0%)50 (8.6%)22 (0.4%)13 (5.9%)0.16Roma (20.0%)20 (0.0%)13 (5.9%)0.16Pathomary Condition (11000)50 (8.6%)23 (0.0%)13 (5.9%)0.16Namely (20.0%)13 (2.6%)13 (6.0%)0.16Roma (20.0%)13 (5.9%)13 (5.9%)13 (5.9%)					
IDEN IDEN IDEN IDEN IDEN Haufh Tacility 254 (43.9%) 12 (297.7%) 112 (96.7%) 009 No 225 (56.1%) 216 (60.3%) 109 (49.3%) 009 No 225 (56.1%) 216 (60.3%) 109 (49.3%) 001 Services 433 (23.0%) 55 (15.0%) 77 (34.8%) 001 Yes 400 (76.0%) 208 (38.2%) 142 (64.3%) 0.99 No 6 (1.0%) 4 (1.1%) 2 (0.5%) 0.99 No 6 (1.0%) 303 (84.6%) 187 (84.6%) 0.99 HW 13 (2.3%) 8 (2.2%) 5 (3.3%) 0.83 Cardiac Candition 13 (2.3%) 12 (3.4%) 13 (5.0%) 0.99 HW 13 (2.3%) 12 (3.4%) 13 (3.0%) 0.83 Pulmonary Condition 13 (2.3%) 12 (3.4%) 0.83 Pulmonary Condition 10 (2.4%) 10 (3.0%) 0.33 Pulmonary Condition 10 (2.4%) 10 (3.0%) 0.20 No 2		, ,			-0.001
Paint Transferred from Another0.009Heath Pacify12 (50,7%)12 (50,7%)Ne25 (56,1%)12 (50,7%)12 (50,7%)No26 (60,3%)10 (90,3%)12 (50,7%)Patient Transported by PrehospialServices33 (32,0%)50 (50,5%)77 (34,8%)-Services40 (76,0%)28 (83,2%)12 (54,3%)-No60,0%41,1%)20 (94,3%)Maring10 (30,1%)12 (34,0%)12 (54,0%)0.98Patt Matical History12 (3,4%)12 (3,4%)0.980.98Cardia Condition13 (2,3%)12 (3,4%)13 (3,6%)0.93Cardia Condition13 (2,3%)12 (3,4%)13 (3,6%)0.93Renal Condition13 (2,3%)12 (3,4%)0.930.93Renal Condition10 (2,5%)10 (16,5%)0.330.93Renal Condition10 (2,5%)0.100.930.93Renal Condition10 (2,5%)0.030.930.93Renal Condition10 (2,5%)0.030.930.93Cancer10 (0,5%)10 (6,5%)0.230.93Cancer10 (3,5%)10 (6,5%)0.160.93Cancer10 (3,5%)10 (3,5%)0.160.16Cancer10 (3,5%)10 (3,5%)0.160.16Cancer10 (3,5%)10 (3,5%)10 (3,5%)0.16Cancer10 (3,5%)10 (3,5%)10 (3,5%)0.16Cancer </td <td>•</td> <td>15 (14-15)</td> <td>15 [14-15]</td> <td>14 [14-15]</td> <td><0.001</td>	•	15 (14-15)	15 [14-15]	14 [14-15]	<0.001
Heading142 (39,7%)142 (50,7%)12 (50,7%)No109 (40,3%)109 (40,3%)No109 (40,3%)109 (40,3%)No133 (20,0%)56 (15,6%)70 (4,3%)Striker133 (20,0%)56 (15,6%)70 (4,3%)Striker140 (50,6%)12 (6,3%)12 (6,3%)No61 (10,9)12 (3,5%)12 (6,3%)Mitting112 (3,4%)12 (3,4%)0,38Cardia Condition13 (2,3%)12 (3,4%)13 (3,6%)0,38Cardia Condition10 (2,3%)12 (3,4%)10 (3,6%)0,38Cardia Condition10 (2,3%)10 (2,3%)10 (3,6%)0,38Read Condition10 (2,3%)10 (2,3%)0,14%0,38Read Condition10 (2,3%)10 (2,3%)0,14%0,38Read Condition10 (2,3%)10 (2,3%)0,16%0,38Read Condition10 (2,3%)10 (2,3%)0,16%0,38Read Condition10 (2,3%)10 (2,3%)0,16%0,38Read Condition10 (2,3%)10 (2,3%)0,16%0,38Read Condition10 (2,3%)10 (2,3%)0,16%0,16%Read Condition10 (2,3%)10 (2,3%)10 (2,3%)10 (2,3%)Read Condition10 (2,3%)10 (2,3%)10 (2,3%)10 (2,3%)Read Condition10 (2,3%)10 (2,3%)10 (2,3%)10 (2,3%)Read Condition15 (5,4%)10 (2,3%)10 (2,3%)10 (2,3%)Read Condia Condition15 (2,4%) <td></td> <td></td> <td></td> <td></td> <td>0.000</td>					0.000
Yes225 (So.1%)216 (60.3%)109 (49.3%)NoPatient Transported by PrehospitalFatient Transported by Prehospital50 (5.6%)77 (54.8%)Services440 (76.0%)298 (83.2%)142 (64.3%)Yes440 (76.0%)298 (83.2%)142 (64.3%)No61 (1.0%)41 (1.1%)20 (9%)Wissing157 (84.6%)0.99International (1.0%)13 (2.3%)8 (2.2%)157 (84.6%)0.98Cardiac Condition13 (2.3%)12 (3.4%)11 (5.0%)0.33Pulmonary Condition6 (1.0%)9 (2.5%)41 (1.8%)0.53Renal Condition1 (0.2%)3 (0.8%)3 (1.4%)0.53Neurologic Condition1 (0.2%)1 (0.3%)0 (0.0%)0.00Neurologic Condition1 (0.2%)0 (0.0%)1 (0.5%)0.20Cardae Condition1 (0.6%)28 (9%)13 (5.6%)0.61Cardae Condition1 (0.6%)29 (80.7%)13 (5.6%)0.61Cardae Condition1 (0.6%)24 (9.5%)13 (5.6%)0.61Cardae Condition Daring42 (76.5%)28 (9%)13 (5.6%)0.61Sergent EC Treatment During43 (76.5%)23 (70.4%)19 (86.4%)<0.001					0.009
No	-				
Patient ServicesSolon 13 (23.0%)Solon 15 (5.6%)Y cas 14 (24.3%)Solon 14 (24.3%)Yes440 (76.0%)298 (83.2%)142 (64.3%)YNon40 (96.0%)41.1%)20.0%)YNon40 (96.0%)30 (84.6%)15 (20.9%)0.98Bit West13 (2.3%)30 (2.4%)15 (2.5%)0.93Cardiac Condition61 (0.9%)20.2%)41.0%)0.33Pulmony Condition61 (0.9%)20.0%)41.0%)0.58Real Condition10.2%)10.0%)0.0%)0.0%Cardiac Condition10.0%)0.0%)0.0%0.0%Real Condition10.0%)0.0%0.0%0.0%Cardiac Condition10.0%)10.0%0.0%0.0%Cardiac Condition10.0%)10.0%0.0%0.0%Cardiac Condition10.0%)10.0%0.0%0.0%Cardiac Condition10.0%)10.0%0.0%0.0%Cardiac Condition10.0%10.0%0.0%0.0%Cardiac Condition10.0%10.0%0.0%0.0%Cardiac Condition10.0%10.0%0.0%0.0%Cardiac Condition10.0%10.0%0.0%0.0%Cardiac Condition10.0%10.0%0.0%0.0%Cardiac Condition10.0%10.0%1.0%0.0%Conde Condition10.0%10.0%1.0%1.0%Conde Condition10.0%10.0%1.0%1.0%		325 (56.1%)	216 (60.3%)	109 (49.3%)	
Service13 (23.0%)56 (15.0%)77 (34.8%)Yes40 (76.0%)28 (83.2%)142 (64.3%)No6 (1.0%)4 (1.1%)2 (0.9%)Missing					
<table-row>Yes440 (76.9%)298 (83.2%)142 (44.3%)Jet and the set of /table-row>					<0.001
No6 (1.0%)4 (1.1%)2 (0.9%)Missing900 (84.6%)30 (84.6%)90 (84.6%)0.98Part Medical History*13 (2.3%)8 (2.2%)5 (2.3%)0.98Cardia Condition13 (2.3%)12 (3.4%)11 (5.0%)0.33Cardia Condition13 (2.3%)12 (3.4%)11 (5.0%)0.33Renal Condition13 (2.3%)2 (2.5%)4 (1.6%)0.33Renal Condition10 (0.2%)10 (0.5%)0.0%)0.55Renal Condition10 (0.2%)0.00%)0.0%0.20Diabetes5 (0.9%)0.00%)10 (0.5%)0.20Concer0 (0.0%)0.00%)10 (0.5%)0.20Other40 (6.9%)28 (9.8%)12 (5.4%)0.27Buth Injury (BI)50 (8.6%)37 (10.3%)13 (5.9%)-Diabetes50 (8.6%)32 (8.0%)13 (5.9%)-Unter Injury (BI)50 (8.6%)32 (8.0%)19 (86.4%)<0.01	Services	133 (23.0%)	56 (15.6%)	77 (34.8%)	
Missing 490 (84.6%) 303 (84.6%) 187 (84.6%) 0.99 Park Medical History ^b 13 (2.3%) 8 (2.2%) 5 (2.3%) 0.98 Cardiac Condition 13 (2.3%) 8 (2.2%) 5 (2.3%) 0.33 Pulmonary Condition 6 (1.0%) 9 (2.5%) 4 (1.8%) 0.58 Renal Condition 1 (0.2%) 1 (0.3%) 0 (0.0%) 0.43 Neurologic Condition 1 (0.2%) 1 (0.3%) 0 (0.0%) 0.43 Diabetes 5 (0.9%) 0 (0.0%) 10 (0.5%) 0.20 Cancer 0 (0.0%) 0 (0.0%) 10 (0.5%) 0.20 Cancer 0 (0.0%) 28 (7.8%) 130 (86.0%) 0.27 Mechanism of Injury 49 (6.2%) 28 (8.9%) 13 (5.4%) 0.16 Blant Flipury (B) 50 (8.6%) 32 (8.9%) 30 (13.6%) <0.01	Yes	440 (76.0%)	298 (83.2%)	142 (64.3%)	
Part NetworkPonce40 (84.6%)30 (84.6%)187 (84.6%)0.99Nome13 (2.3%)8 (2.3%)5 (2.3%)0.98Cardiac Condition13 (2.3%)12 (3.4%)11 (5.0%)0.33Pulmonary Condition16 (1.0%)9 (2.5%)11 (5.0%)0.55Renal Condition10.2%)3 (0.4%)3 (1.4%)0.55Neurologi Condition10.2%)10.3%)0.00%)0.0%)0.43Diabets5 (0.9%)0 (0.0%)10 (0.0%)0.202.6Cancer0 (0.0%)28 (7.8%)10 (5.6%)0.27Other0 (0.0%)29 (0.0%)12 (5.4%)0.27Mechanism of Injury470 (82.7%)29 (00.7%)13 (5.9%)0.16Dinter Jourg MonoP27 (1.3%)13 (5.9%)0.16Penetrating Injury (PI)50 (8.6%)21 (2.0%)10 (8.4%)Other one-Bland Non-PI21 (2.0%)30 (3.6%)-0.01Stringt For Stringt MonoPI13 (2.5%)21 (8.0%)Vetor word Bandom For21 (3.6%)21 (8.0%)Vetor word Bandom For21 (8.0%)10 (8.1%)Stringt For Stringt MonoP13 (2.5%)21 (8.0%)Vetor word Bandom For21 (8.0%)21 (8.0%) </td <td>No</td> <td>6 (1.0%)</td> <td>4 (1.1%)</td> <td>2 (0.9%)</td> <td></td>	No	6 (1.0%)	4 (1.1%)	2 (0.9%)	
None400 (46.%)303 (46.%)127 (36.%)0.99HV13 (2.3%)12 (3.4%)11 (5.0%)0.33Cardiac Condition13 (2.3%)12 (3.4%)11 (5.0%)0.33Pulmonary Condition6 (1.0%)9 (2.5%)4 (1.8%)0.58Renal Condition10.2%)10 (3%)0 (0.0%)0.43Neurologic Condition10.2%)10 (3%)0 (0.0%)0.20Stabetes0 (0.0%)0 (0.0%)0 (0.5%)0.20Cancer0 (0.0%)0 (0.0%)10 (5.5%)0.27Chenary0 (0.6%)28 (7.8%)13 (5.6%)0.27Other479 (8.2.%)28 (7.8%)13 (6.6%)0.27Penetrating Injury (PI)50 (8.6%)28 (7.8%)16 (8.6%)0.7Penetrating Injury (PI)50 (8.6%)28 (7.8%)16 (8.4%)0.01Other13 (5.6.7%)28 (7.8%)13 (6.6.%)0.01Within 6 h136 (2.5%)10 (2.6.%)30 (13.6%)1YesImage and Experimental During433 (7.5.%)25 (70.4%)13 (6.0.%)<0.01	Missing				
HIV13 (2.3%)8 (2.2%)5 (2.3%)0.98Cardiac Condition13 (2.3%)11 (5.0%)0.33Cardiac Condition6 (1.0%)9 (2.5%)11 (5.0%)0.38Renal Condition1 (0.2%)3 (0.9%)3 (1.4%)0.55Renal Condition1 (0.2%)1 (0.9%)0 (0.0%)0.43Diabetes5 (0.9%)0 (0.0%)1 (0.5%)0.43Cancer0 (0.0%)0 (0.0%)1 (0.5%)0.27Mechanism of Injury0 (0.0%)28 (98.0%)190 (86.0%)0.16Blunt Injury (BI)50 (8.6%)37 (10.3%)13 (5.9%)-Determing Injury (PI)50 (8.6%)32 (0.9%)13 (5.6%)-Other Non-Bl and Non-PIEmergent EC Treatment During436 (5.5%)252 (70.4%)19 (66.4%)<0.01	Past Medical History ^b				
Cardiacondition13 (239)12 (349)11 (509)0.33Pulmonar Condition6 (1.0%)9 (2.5%)4 (1.8%)0.58Neurologic Condition1 (0.2%)1 (0.3%)0 (0.0%)0.43Neurologic Condition5 (0.9%)0 (0.0%)0 (0.0%)0.20Cancer0 (0.0%)0 (0.0%)0 (0.0%)0.20Cancer0 (0.6%)0 (0.0%)0 (0.0%)0.20Cancer0 (0.6%)0 (0.0%)12 (5.4%)0.27Mechanism of Injury40 (6.9%)28 (7.8%)190 (86.0%)0.16Blunt Injury (B)50 (8.6%)32 (8.9%)13 (5.9%)-Penetrating Injury (D)50 (8.6%)32 (8.9%)18 (8.1%)-Other50 (8.6%)32 (8.9%)30 (1.8.6%)Within 6 h136 (23.5%)106 (29.6%)30 (1.8.6%)YesNoStrigt Consultation During156 (54.4%)160 (9.0%)15 (68.3%)NoTansferred to Another Health Facility11 (0.9%)51 (4.4%)62 (9.3%)Disoldion16 (54.4%)53 (7.0%)62 (28.1%) </td <td>None</td> <td>490 (84.6%)</td> <td>303 (84.6%)</td> <td>187 (84.6%)</td> <td>0.99</td>	None	490 (84.6%)	303 (84.6%)	187 (84.6%)	0.99
Pulmany Condition6 (1%)9 (2.%)4 (1.8%)0.58Renal Condition1 (0.2%)3 (0.8%)3 (1.4%)0.55Neurologic Condition1 (0.2%)1 (0.5%)0.20Diabets5 (0.9%)0 (0.0%)1 (0.5%)0.20Cancer0 (0.0%)0 (0.0%)0 (0.0%)NAOther4 (0.6%)0 (0.0%)10 (0.5%)0.27Mechanism of Injury40 (6.9%)28 (7.8%)13 (5.9%)12Blunt Injury (BI)50 (8.6%)37 (10.3%)13 (5.9%)1Other No-81 and Non-PI50 (8.6%)32 (0.2%)18 (8.1%).Penetrating Injury (BI)50 (8.6%)252 (70.4%)19 (86.4%)Other No-81 and Non-PI10 (20.5%)30 (13.6%) Emergent ECTreatment During 443 (76.5%)10 (60.2%)30 (13.6%)Within 6 h10 52 (3.0%)10 (60.9%)30 (13.6%)Straged Consultation During31 (54.4%)12 (60.9%)46 (20.8%)<	HIV	13 (2.3%)	8 (2.2%)	5 (2.3%)	0.98
Pulmany Condition6 (1%)9 (2.%)4 (1.8%)0.58Renal Condition1 (0.2%)3 (0.8%)3 (1.4%)0.55Neurologic Condition1 (0.2%)1 (0.5%)0.20Diabets5 (0.9%)0 (0.0%)1 (0.5%)0.20Cancer0 (0.0%)0 (0.0%)0 (0.0%)NAOther4 (0.6%)0 (0.0%)10 (0.5%)0.27Mechanism of Injury40 (6.9%)28 (7.8%)13 (5.9%)12Blunt Injury (BI)50 (8.6%)37 (10.3%)13 (5.9%)1Other No-81 and Non-PI50 (8.6%)32 (0.2%)18 (8.1%).Penetrating Injury (BI)50 (8.6%)252 (70.4%)19 (86.4%)Other No-81 and Non-PI10 (20.5%)30 (13.6%) Emergent ECTreatment During 443 (76.5%)10 (60.2%)30 (13.6%)Within 6 h10 52 (3.0%)10 (60.9%)30 (13.6%)Straged Consultation During31 (54.4%)12 (60.9%)46 (20.8%)<	Cardiac Condition		12 (3.4%)	11 (5.0%)	0.33
Rend condition1 (0.2%)3 (0.8%)3 (1.4%)0.55Neurologic Condition1 (0.2%)1 (0.3%)0 (0.0%)0.43Diabetes5 (0.9%)0 (0.0%)1 (0.5%)0.20Cancer0 (0.0%)0 (0.0%)10 (0.0%)0.74Other40 (6.9%)28 (7.8%)12 (5.4%)0.27Mechanism of Injury40 (0.6%)28 (7.8%)13 (5.9%)0.16Blunt Injury (BI)50 (8.6%)32 (8.0%)18 (8.1%)-Penetrating Injury (PI)50 (8.6%)22 (2.0.4%)18 (8.1%)-CherOtherWithin 6 h136 (3.5%)106 (29.6%)30 (13.6%)-VerNoStrigt Consultation During156 (4.4%)126 (3.0%)30 (13.6%)-NoStrigt Consultation During156 (4.4%)128 (0.9%)NoNoStrigt Consultation During16 (54.4%)123 (70.7%)6 (28.1%)NoNoStrigt Consultation During16 (54.4%)13 (30.6%) <td></td> <td></td> <td></td> <td></td> <td></td>					
Neurologic Condition10.2%)10.3%)0.0%)0.43Diabetes5.0%)0.0%)10.5%)0.20Cancer0.0%)0.0%)0.0%)N/AOther40.6%)28.7%)28.0%)12.6.4%)0.27Blunt Injury (BI)50.8.6%)28.0%)13.6.5%)Penetrating Injury (PI)50.8.6%)28.0%)13.6.5%)Other Non-BI and Non-PI13.6.2.5%)19.1.66.4%)<0.001	-				
Diabetes5(0.9%)0(0.0%)1(0.5%)0.20Cancer0(0.0%)0(0.0%)0(0.0%)N/ACancer0(0.0%)28(7.8%)12(5.4%)0.27Mechanism of Injury479 (82.7%)289 (80.7%)190 (86.0%)0.16Blunt Injury (BI)50 (8.6%)37 (10.3%)13 (5.9%)Penetrating Injury (PI)50 (8.6%)32 (8.9%)13 (5.9%)Others-Bl and Non-PIEmergent EC Treatment During43 (75.5%)252 (70.4%)30 (13.6%)within 6 h252 (70.4%)30 (13.6%)YesNoYesIsingcial Consultation During315 (54.4%)140 (39.1%)No<					
Cancer00 <td>-</td> <td></td> <td></td> <td></td> <td></td>	-				
Other40 (6.9%)28 (7.8%)12 (5.4%)0.27Mechanism of Injury479 (82.7%)289 (80.7%)190 (86.0%)0.16Blunt Injury (BJ)50 (8.6%)37 (0.3%)13 (5.9%).Penetrating Injury (PJ)50 (8.6%)32 (8.9%)18 (8.1%).Other Non-BI and Non-PIUEmergent EC Treatment During437 (76.5%)252 (70.4%)191 (86.4%)<0.001within 6 h136 (23.5%)106 (29.6%)30 (13.6%)<0.001YesUNoUSurgical Consultation During155 (4.4%)140 (39.1%)75 (79.2%)<0.001within 6 h264 (45.6%)218 (60.9%)46 (20.8%)<0.001yesUU10015.168.3%)<0.001YesUU10.4%)50 (70.7%)62 (28.1%)<0.001Disposition316 (54.4%)253 (70.7%)62 (28.1%)<0.001Disposition316 (64.6%)253 (70.7%)62 (28.1%)<0.001Disposition316 (64.6%)253 (70.7%)62 (28.1%)<0.001Disposition316 (54.4%)253 (70.7%)62 (28.1%)<0.001Disposition316 (64.6%)253 (70.7%)62 (28.1%)<0.001Disposition316 (64.6%)253 (70.7%)62 (28.1%)<0.001Disposition316 (64.6%)253 (70.7%)62 (28.1%)<0.001Disposition316 (64.4%)253 (70.7%)62 (28.1%)<0.001Disposition <td></td> <td></td> <td></td> <td></td> <td></td>					
Mechanism of Injury479 (82.7%)289 (80.7%)190 (86.0%)0.16Blunt Injury (BI)50 (8.6%)37 (10.3%)13 (5.9%)-Penetrating Injury (PI)50 (8.6%)32 (8.9%)18 (8.1%)-Other Non-BI and Non-PIEmergent EC Treatment During443 (76.5%)252 (70.4%)191 (86.4%)-Within 6 h136 (32.5%)252 (70.4%)30 (13.6%)YesSurgical Consultation During155 (54.4%)140 (39.1%)175 (79.2%)<0.001		· ·			
Blunt Injury (BI) 50 (8.6%) 37 (10.3%) 13 (5.9%) Penetrating Injury (PI) 50 (8.6%) 32 (8.9%) 18 (8.1%) Penetrating Injury (PI) 50 (8.6%) 32 (8.9%) 191 (86.4%) <0.001				• •	
Penetrating Injury (PI) 50 (8.6%) 32 (8.9%) 18 (8.1%) Other Non-B1 and Non-P1					0.16
Other Non-PI 443 (76.5%) 252 (70.4%) 191 (86.4%) <0.001					
Emergent EC Treatment During443 (76.5%)252 (70.4%)191 (86.4%)<0.001within 6 h136 (23.5%)106 (29.6%)30 (13.6%)'YesNoSurgical Consultation During15 (54.4%)140 (39.1%)46 (20.8%)within 6 h <t< td=""><td></td><td>50 (8.6%)</td><td>32 (8.9%)</td><td>18 (8.1%)</td><td></td></t<>		50 (8.6%)	32 (8.9%)	18 (8.1%)	
within 6 h136 (23.5%)106 (29.6%)30 (13.6%)YesNoSurgical Consultation During151 (54.4%)140 (39.1%)175 (79.2%)<0.011		443 (76 5%)	252 (70 4%)	101 (86 4%)	<0.001
Yes No					<0.001
NoSeries of the series of the ser		130 (23.3%)	100 (29.0%)	30 (13.0%)	
Surgical Consultation During315 (54.4%)140 (39.1%)175 (79.2%)<0.001within 6 h264 (45.6%)218 (60.9%)46 (20.8%)Yes </td <td></td> <td></td> <td></td> <td></td> <td></td>					
within 6 h 264 (45.6%) 218 (60.9%) 46 (20.8%) Yes No No No No No No No Second			1 40 (00 200)		0.001
Yes No Disposition 316 (54.4%) 253 (70.7%) 62 (28.1%) <0.001					<0.001
No Disposition 316 (54.4%) 253 (70.7%) 62 (28.1%) <0.001 Discharged from EC 236 (40.6%) 84 (23.5%) 151 (68.3%)		264 (45.6%)	218 (60.9%)	46 (20.8%)	
Disposition 316 (54.4%) 253 (70.7%) 62 (28.1%) <0.001 Discharged from EC 236 (40.6%) 84 (23.5%) 151 (68.3%) <1 Admitted to Hospital 71.2% 51.4% 20.9% <1 Transferred to Another Health Facility 110.9% 51.4% 62.7% <1 Died 30.5% 30.8% 60.0% $<-$ Eloped or Withdrew 81.4% 82.2% 00.0% $<-$ Missing $<$ <0.001 $<$ <0.001 COVID-19 Restrictions 399 (68.9%) 266 (74.3%) 133 (60.2%) <0.001 Before COVID-19 180 (31.1%) 92 (25.7%) 88 (39.8%) $<-$ During COVID-19 211 (38.2%) 0 211 (100%)NAReceived testing 328 (61.8%) 358 (100%) 000 $<$ Not Tested $=$ $=$ $=$ $=$ HV Testing Outcome $=$ $=$ $=$ $=$ Regative $=$ $=$ $=$ $=$ Positive $=$ $=$ $=$ $=$ Positive $=$					
Discharged from EC 236 (40.6%) 84 (23.5%) 151 (68.3%) Admitted to Hospital 7 (1.2%) 5 (1.4%) 2 (0.9%) Transferred to Another Health Facility 11 (0.9%) 5 (1.4%) 6 (2.7%) Died 3 (0.5%) 3 (0.8%) 0 (0.0%) - Eloped or Withdrew 8 (1.4%) 8 (2.2%) 0 (0.0%) - Missing COVID-19 Restrictions 399 (68.9%) 266 (74.3%) 133 (60.2%) <0.001					
Admitted to Hospital 7 (1.2%) 5 (1.4%) 2 (0.9%) Transferred to Another Health Facility 11 (0.9%) 5 (1.4%) 6 (2.7%) Died 3 (0.5%) 3 (0.8%) 0 (0.0%) Eloped or Withdrew 8 (1.4%) 8 (2.2%) 0 (0.0%) Missing COVID-19 Restrictions 399 (68.9%) 266 (74.3%) 133 (60.2%) <0.001	•	316 (54.4%)		62 (28.1%)	< 0.001
Transferred to Another Health Facility 11 (0.9%) 5 (1.4%) 6 (2.7%) Died 3 (0.5%) 3 (0.8%) 0 (0.0%) Eloped or Withdrew 8 (1.4%) 8 (2.2%) 0 (0.0%) Missing - - - COVID-19 Restrictions 399 (68.9%) 266 (74.3%) 133 (60.2%) <0.001	Discharged from EC	236 (40.6%)	84 (23.5%)	151 (68.3%)	
Died 3 (0.5%) 3 (0.8%) 0 (0.0%) Eloped or Withdrew 8 (1.4%) 8 (2.2%) 0 (0.0%) Missing COVID-19 Restrictions 200 CVID-19 180 (31.1%) 266 (74.3%) 133 (60.2%) <0.001	Admitted to Hospital			2 (0.9%)	
Eloped or Withdrew 8 (1.4%) 8 (2.2%) 0 (0.0%) Missing	Transferred to Another Health Facility	11 (0.9%)	5 (1.4%)	6 (2.7%)	
Missing 266 (74.3%) 133 (60.2%) <0.001		3 (0.5%)	3 (0.8%)	0 (0.0%)	
Missing Score <	Eloped or Withdrew	8 (1.4%)	8 (2.2%)	0 (0.0%)	
Before COVID-19 180 (31.1%) 92 (25.7%) 88 (39.8%) During COVID-19 HIV Testing 221 (38.2%) 0 221 (100%) NA Received testing 358 (61.8%) 358 (100%) 0100%) Not Tested 173 (78.3%) NA Negative 13 (5.9%) Positive 55 (15.8%)	Missing				
Before COVID-19 180 (31.1%) 92 (25.7%) 88 (39.8%) During COVID-19 HIV Testing 221 (38.2%) 0 221 (100%) NA Received testing 358 (61.8%) 358 (100%) 0100%) Not Tested 173 (78.3%) NA Negative 13 (5.9%) Positive 55 (15.8%)	COVID-19 Restrictions	399 (68.9%)	266 (74.3%)	133 (60.2%)	< 0.001
During COVID-19 NA HIV Testing 221 (38.2%) 0 221 (100%) NA Received testing 358 (61.8%) 358 (100%) 0 (100%)					
HIV Testing 221 (38.2%) 0 221 (100%) NA Received testing 358 (61.8%) 358 (100%) 0 (100%)					
Received testing 358 (61.8%) 358 (100%) 0 (100%) Not Tested 173 (78.3%) NA HIV Testing Outcome 173 (78.3%) NA Negative 13 (5.9%) 35 (15.8%)	0	221 (38.2%)	0	221 (100%)	NA
Not Tested 173 (78.3%) NA HIV Testing Outcome 173 (78.3%) NA Negative 13 (5.9%) S Positive 35 (15.8%) S	0				
HIV Testing Outcome 173 (78.3%) NA Negative 13 (5.9%) Positive 35 (15.8%)	0	000 (01.070)	555 (10070)	0 (10070)	
Negative 13 (5.9%) Positive 35 (15.8%)				173 (78 3%)	NΔ
Positive 35 (15.8%)	-				1411
	-				
	Positive Indeterminate or No Result			55 (13.8%)	

^a Injury requiring hospital admission for asmission for definitive management [37].
 ^b The percentages for these variables do not add up to 100% because the categories within the variable are not mutually exclusive.

Table 2

Factors associated with HIV testing*.

	Odds raAuthors'		
Variable	[95% CI]	P-Value	
Sex			
Female	Reference	Reference	
Male	1.69 [1.02-2.78]	0.04	
Hours Between Injury and	1.02 [0.99-1.06]	0.16	
Presentation (+10 h)			
Kampala Trauma Score (+1	0.70 [0.55-0.90]	0.004	
Score)			
Patient Transported by	Reference	Reference	
Prehospital Services	2.07 [1.28-3.35]	0.003	
No			
Yes			
Surgical Consultation			
During First 6 h	Reference	Reference	
No	3.13 [1.99-4.94]	< 0.001	
Yes			
Disposition			
Admitted to Hospital	Reference	Reference	
Discharged from emergency	0.28 [0.18-0.43]	< 0.001	
centre			

*, Patients with a disposition other than "Discharged from emergency centre" or "Admitted to Hospital" (n=21) or with missing disposition data (n=8) were excluded from analysis.

during EC care is scaled up [24,29]. Studies evaluating EC-based HIV testing in lower-resourced settings have shown high testing acceptability and feasibility in emergency centres; there may be the ability to do so in the Rwandan context [11,24]. Furthermore, providing HIV testing to more patients seeking care for injuries in the EC may target a disproportionally high-risk patient population of younger adults and other high-risk individuals, which could server to help progress Rwanda's national strategic plan for HIV control [30].

During the COVID-19 pandemic, the proportion of patients who underwent HIV testing increased. In this study, severity of illness was higher and there was a greater number of hospital admissions during the intra-COVID-19 study period, which was associated with increased HIV testing. Another study at the same EC site found that during the intra-COVID-19 pandemic, injury care had higher disease burdens and increased inpatient admission with more significant resource requirements than the pre-COVID-19 period [19]. It is unclear if COVID-19 may have influenced clinician decision making related to HIV testing. While other studies have reported challenges to HIV screening and testing programs during the pandemic due to limited in-person interactions, community-based testing, and outreach, the EC is a unique venue that has maintained healthcare access and continued testing efforts [25,31]. Although the increase in HIV testing observed during the pandemic suggests a system benefit, it is essential to note that the sampling frame in the present data limits conclusions on the pandemic's total impact on HIV testing in Rwanda. Further longitudinal studies are needed.

There are limitations to this study. This research was nested in a cohort study designed to evaluate acute injury care at the study site. Although the assessment of HIV testing was an *a priori* outcome of interest data to investigate individual provider practice patterns or decision making that may have influence attainment of HIV testing was not available beyond the patient specific data. To address this future qualitative research should be conducted to assess physician perceptions and decision-making process for HIV testing within the emergency care setting. Furthermore, the current analysis only focused on patient population presenting with injuries. Patients presenting with injuries may differ from those presenting with medical complaints as they are often younger and predominately male, which represent key groups for HIV testing initiatives in Africa. Additionally, due to the COVID-19 pandemic, there was an interruption in data collection and the results must be interpreted in the context of this event.

The methods did not allow for the assessment of patients who declined to test for HIV, as such, testing acceptability was not evaluated and could be of importance in designing enhanced EC testing approaches. In addition, this study did not assess linkage to HIV care after the identification of a PLHIV in the EC. Linking patients to care after identification is key in impacting HIV programming across the cascade of care and should be evaluated in future studies. Finally, this data represents patients at a single centre tertiary care facility with access to relatively well-resourced emergency care and HIV testing resources and as such extrapolation to other health facilities is uncertain.

Conclusion

In the studied EC injury population in Kigali, Rwanda, there was a modest level of HIV testing completed. EC-based physician directed HIV testing was more likely among males and those requiring greater treatment resources. Patients who were discharged, and those with less severe injuries were less likely to have received HIV testing. Given the persistent need for improved HIV case identification and access to highrisk target groups, the current data may be used to inform the development of EC-based HIV testing approaches in Rwanda and other similar settings.

Dissemination of results

The results of this study were shared with the ED at the study site through a departmental presentation. Preliminary results from this work were presented at the Society for Academic Emergency Medicine.

Authors' contribution

Authors contributed as follow to the conception or design of the work; the acquisition, analysis, or interpretation of data for the work; and drafting the work or revising it critically for important intellectual content: AB contributed 25 %; CGM, OT, CU and ARA 15%; and SJ, ZM, VN, DU, MN and AS, 2.5%. All authors approved the version to be published and agreed to be accountable for all aspects of the work.

Declaration of Competing Interest

The authors have no conflicts of interest. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the views of or any academic organisations. The funders played no role in the collection, analysis or reporting of the data.

Acknowledgments

The authors would like to thank the emergency centre staff at the Centre Hospitalier Universitaire de Kigali for all their help and support of the study as well as the patient-participants. Funding for this research was provided through Brown Physicians Incorporated and Brown Emergency Medicine research grants. ARA was supported by funding from the National Institutes of Health, National Institute of Allergy and Infectious Diseases (1K23AI145411). The funders had no role in the study design, data collection, or reporting processes.

References

- STAR Initiative, Unitaid, WHO Knowing your status-then and now: realizing the potential of HIV self-testing. Geneva: STAR Initiative, Unitaid, World Health Organization; 2018.
- [2] HIV/AIDS World health organization. World Health Organization; 2022. www.afro.who.int/health-topics/hivaids.
- [3] Global AIDS Update. Seizing the Moment: Tackling entrenched inequalities to end epidemics. 2022 https://www.unaids.org/sites/default/files/media_asset/ 2020_global-aids-report_en.pdf.

- [4] Giguère K, Eaton JW, Marsh K, Johnson LF, Johnson CC, Ehui E, et al. Trends in knowledge of HIV status and efficiency of HIV testing services in sub-Saharan Africa, 2000-20: a modelling study using survey and HIV testing programme data. Lancet HIV 2021;8(5):e284–93 [Intermet]Available from: https://www. sciencedirect.com/science/article/pii/S2352201820303155.
- [5] Chamie G, Napierala S, Agot K, Thirumurthy H. HIV testing approaches to reach the first UNAIDS 95% target in sub-Saharan Africa. Lancet HIV 2021;8(4):e225–36 [Internet]Available from:. doi:10.1016/S2352-3018(21)00023-0.
- [6] Hansoti B, Kelen GD, Quinn TC, Whalen MM, DesRosiers TT, Reynolds SJ, et al. A systematic review of emergency department based HIV testing and linkage to care initiatives in low resource settings. PLoS One 2017;12(11):1–11 [Internet]Available from:. doi:10.1371/journal.pone.0187443.
- [7] Mills EJ, Beyrer C, Birungi J, Dybul MR. Engaging men in prevention and care for HIV/AIDS in Africa. PLoS Med 2012;9(2):1–4.
- [8] Tang N, Stein J, Hsia RY, Maselli JH, Gonzales R. Trends and characteristics of US emergency department visits, 1997–2007. JAMA 2010;304(6):664–70 [Internet]Aug 11Available from:. doi:10.1001/jama.2010.1112.
- [9] Obermeyer Z, Abujaber S, Makar M, Stoll S, Kayden SR, Wallis LA, et al. Emergency care in 59 low- and middle-income countries: a systematic review. Bull World Health Organ 2015;93(8) Aug. 577–586G.
- [10] R Aluisio A, Rege S, T Stewart B, Kinuthia J, Levine AC, Mello MJ, et al. Prevalence of HIV-seropositivity and associated impact on mortality among injured patients from low-and middle-income countries: a systematic review and meta-analysis. Curr HIV Res 2017;15(5):307–17.
- [11] Hansoti B, Stead D, Parrish A, Reynolds SJ, Redd AD, Whalen MM, et al. HIV testing in a South African emergency department: a missed opportunity. PLoS One 2018;13(3):e0193858.
- [12] Sawe HR, Mfinanga JA, Ringo FH, Mwafongo V, Reynolds TA, Runyon MS. HIV counselling and testing practices for children seen in an urban emergency department of a tertiary referral hospital in Dar es Salaam, Tanzania: a retrospective cross-sectional study. BMJ Open 2016;6(2):1–6.
- [13] Nakanjako D, Kyabayinze DJ, Mayanja-Kizza H, Katabira E, Kamya MR. Eligibility for HIV/AIDS treatment among adults in a medical emergency setting at an urban hospital in Uganda. Afr Health Sci 2007;7(3):124–8.
- [14] Joint United Nations Programme on HIV/AIDS Global report: UNAIDS report on the global AIDS epidemic. Joint United Nations Programme on HIV/AIDS; 2010. https://www.unaids.org/globalreport/Global_report.htm.
- [15] Cousins S. The past and present violence of rwanda's HIV epidemic. Lancet HIV 2019;6(1):e10–11.
- [16] Manzi A, Munyaneza F, Mujawase F, Banamwana L, Sayinzoga F, Thomson DR, et al. Assessing predictors of delayed antenatal care visits in Rwanda: a secondary analysis of Rwanda demographic and health survey 2010. BMC Pregnancy Childbirth 2014;14(1):290 [Internet]Available from:. doi:10.1186/1471-2393-14-290.
- [17] Republic of Rwanda Ministry of Health National HIV/AIDS targets 2018-2020-2030. Rwanda Biomedical Center; 2015. https://rbc.gov.rw/IMG/pdf/rwanda_ hiv_aids_2020_and_2030_targets.pdf.
- [18] PHIA. (2019). Rwanda population-based HIV impact assessment 2018-2019. https://phia.icap.columbia.edu/countries/rwanda/; 2020 [accessed 24 September 2021].
- [19] Uwamahoro C, Marques CG, Beeman A, Mutabazi Z, Twagirumukiza FR, Jing L, et al. Injury burdens and care delivery in relation to the COVID-19 pandemic in Kigali, Rwanda: a prospective interrupted cross-sectional study. Afr J Emerg Med 2021 [Internet]Available from:. https://www.sciencedirect.com/science/ article/pii/S2211419×2100063X.

- [20] Aluisio AR, Barry MA, Martin KD, Mbanjumucyo G, Mutabazi ZA, Karim N, et al. Impact of emergency medicine training implementation on mortality outcomes in Kigali, Rwanda: An interrupted time-series study. Afr J Emerg Med 2019;9(1):14– 20 [Internet]Available from:. doi:10.1016/j.afjem.2018.10.002.
- [21] Akay S, Ozturk AM, Akay H. Comparison of modified Kampala trauma score with trauma mortality prediction model and trauma-injury severity score: a National trauma data bank study. Am J Emerg Med 2017;35(8):1056–9 [Internet]Available from:. http://www.sciencedirect.com/science/article/pii/S0735675717301237.
- [22] Gardner A, Forson PK, Oduro G, Stewart B, Dike N, Glover P, et al. Diagnostic accuracy of the Kampala Trauma score using estimated abbreviated injury scale scores and physician opinion. Injury 2017;48(1):177–83 [Internet]Available from:. http://www.sciencediret.com/science/article/pii/S0020138316307616
- [23] Tang OY, Marqués CG, Ndebwanimana V, Uwamahoro C, Uwamahoro D, Lipsman ZW, et al. Performance of prognostication scores for mortality in injured patients in rwanda. West J Emerg Med 2021;22(2):435–44.
- [24] Arbelaez C, Wright EA, Losina E, Millen JC, Kimmel S, Dooley M, et al. Emergency provider attitudes and barriers to universal HIV testing in the emergency department. J Emerg Med 2012;42(1):7–14 [Internet]2009/10/14. Available from:. https://pubmed.ncbi.nlm.nih.gov/19828278.
- [25] Stanford KA, Friedman EE, Schmitt J, Spiegel T, Ridgway JP, Moore M, et al. Routine screening for HIV in an Urban emergency department during the COVID-19 pandemic. AIDS Behav 2020;24(10):2757-9 [Internet]Available from. doi:10.1007/s10461-020-02899-x.
- [26] Champenois K, Cousien A, Cuzin L, Le Vu S, Deuffic-Burban S, Lanoy E, et al. Missed opportunities for HIV testing in newly-HIV-diagnosed patients, a cross sectional study. BMC Infect Dis 2013;13(1):200 [Internet]Available from:. doi:10.1186/1471-2334-13-200.
- [27] Harmon J., Michael M., Kelley G., Heath S.L., Ross-davis K.L., Walter L.A. Characteristics of HIV seroconverters identified. 2021;35(7):255-62.
- [28] Republic of Rwanda Ministry of Health National guidelines for prevention and management of HIV and STIs. Rwanda Biomedical Center; 2016. [accessed 24 September 2021]. https://differentiatedservicedelivery.org/Portals/0/adam/Content/ZNPYs RfC20SQV3xbkQiaow/File/Rwanda%20national%20guidelines%202016.pdf
- [29] Mohareb AM, Patel AV, Laeyendecker OB, Toerper MF, Signer D, Clarke WA, et al. The HIV screening cascade: current emergency department-based screening strategies leave many patients with HIV undiagnosed. JAIDS J Acquir Immune Defic Syndr 2021;87(1) [Internet]Available from: https://journals.lww.com/jaids/ Fulltext/2021/05010/The_HIV_Screening_Cascade_Current_Emergency.19.aspx.
- [30] Republic of Rwanda Ministry of Health National strategic plan on HIV and AIDS: 2018 -2020. Republic of Rwanda Ministry of Health; 2019. https://rbc.gov.rw/ fileadmin/user_upload/stra2019/strategie2019/Rwanda%20Strategic%20Plan%20 for%20HIV%20Extended%20to%202020.pdf, 2016 [accessed 24 September 2021].
- [31] Jiang H, Zhou Y, Tang W. Maintaining HIV care during the COVID-19 pandemic. Lancet HIV 2020;7(5):e308–9 [Internet]Available from. doi:10.1016/ S2352-3018(20)30105-3.
- [32] Kayigamba FR, Bakker MI, Lammers J, Mugisha V, Bagiruwigize E, Asiimwe A, et al. Provider-initiated hiv testing and counselling in Rwanda: acceptability among clinic attendees and workers, reasons for testing and predictors of testing. PLoS One 2014;9(4):1–9.